Kathleen Moore to Quality of Life
This is a "connection" page, showing publications Kathleen Moore has written about Quality of Life.
Connection Strength
0.735
-
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 10; 177:20-31.
Score: 0.638
-
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63.
Score: 0.097